Cargando…
Actual status of veralipride use
During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride ha...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938034/ https://www.ncbi.nlm.nih.gov/pubmed/20852674 |
_version_ | 1782186565244551168 |
---|---|
author | Carranza-Lira, Sebastián |
author_facet | Carranza-Lira, Sebastián |
author_sort | Carranza-Lira, Sebastián |
collection | PubMed |
description | During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules. |
format | Text |
id | pubmed-2938034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-29380342010-09-17 Actual status of veralipride use Carranza-Lira, Sebastián Clin Interv Aging Review During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules. Dove Medical Press 2010 2010-09-07 /pmc/articles/PMC2938034/ /pubmed/20852674 Text en © 2010 Carranza-Lira, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Carranza-Lira, Sebastián Actual status of veralipride use |
title | Actual status of veralipride use |
title_full | Actual status of veralipride use |
title_fullStr | Actual status of veralipride use |
title_full_unstemmed | Actual status of veralipride use |
title_short | Actual status of veralipride use |
title_sort | actual status of veralipride use |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938034/ https://www.ncbi.nlm.nih.gov/pubmed/20852674 |
work_keys_str_mv | AT carranzalirasebastian actualstatusofveraliprideuse |